Stock Screener App

無料 -

インストール

4.76

3.05% -0.15

after-market

アフターアワーズ： 4.80 0.04 +0.84%

An 2 Therapeutics Inc (ANTX)

概要ニュース株価時系列 Financials ディスカッション予測

An 2 Therapeutics Inc (ANTX) 最新ニュース

Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire

Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade

TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade

Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire

Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire

Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire

Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative

Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire

Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline - PR Newswire

Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha

Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan

C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union

Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout - PR Newswire

This Summit Therapeutics Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Friday - Benzinga

Black Diamond Therapeutics Announces Positive Phase 2 - GlobeNewswire

DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial - Business Wire

Relay Therapeutics (Nasdaq: RLAY) shares early zovegalisib vascular anomaly data - Stock Titan

Amplexd Therapeutics Initiates Phase 2 Clinical Trial of Investigational EGCg-Based HPV Therapy - GlobeNewswire

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - GlobeNewswire

Tenaya Therapeutics, Inc. (TNYA) Discusses RIDGE-1 Phase Ib/II Data on TN-401 Gene Therapy for PKP2-Associated ARVCSlideshow (NASDAQ:TNYA) 2026-05-17 - Seeking Alpha

Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026 - PR Newswire

Viridian Therapeutics, Inc. (VRDN) Discusses Positive Top Line Results From REVEAL-2 Phase III Trial in Chronic Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-05-09 - Seeking Alpha

Millennium-linked entities file 13G/A for Tenax Therapeutics (NASDAQ: TENX) reporting ~2% stakes - Stock Titan

Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-Phase 2 Meeting with FDA - GlobeNewswire

Avalo Therapeutics (AVTX) jumps as Phase 2 LOTUS topline results and $375M financing reshape outlook - Quiver Quantitative

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease - Business Wire

Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas - Yahoo Finance

MapLight Therapeutics Completes Enrollment in ZEPHYR Phase 2 Trial for Schizophrenia and Final Patient Visit in IRIS Phase 2 Trial for Autism Spectrum Disorder - Quiver Quantitative

Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire

Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance

Rein's lung-scarring trial reaches 8 patients, expands to 3 countries - Stock Titan

Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting - GlobeNewswire

Compass Therapeutics to Announce Topline Secondary Endpoints from the Phase 2/3 COMPANION-002 Study of Tovecimig in Patients with Biliary Tract Cancer - Investing News Network

Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance

Thryv Therapeutics Commences Patient Dosing in Wave II Clinical Study for Long QT Syndrome and Receives FDA Fast Track Designation for THRV-1268 - BioSpace

Convergent Therapeutics to Present Phase 2 Data for CONV01-α in Lu-PSMA pretreated Metastatic Castration-Resistant Prostate Cancer Patients at the 2026 ASCO Annual Meeting - BioSpace

Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance

Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire

Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire

Black Diamond Therapeutics Announces Oral Presentation of - GlobeNewswire

Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Yahoo Finance

ZEVRA THERAPEUTICS, INC. ($ZVRA) CEO 2025 Pay Revealed - Quiver Quantitative

Sapience Therapeutics Presents First Clinical Results from Phase 2 Study of ST316, First-in-Class β-catenin Antagonist, in Second-Line Colorectal Cancer at the American Association for Cancer Research (AACR) Annual Meeting 2026 - PR Newswire

MapLight Therapeutics: Strong Balance Sheet Ahead of Crucial Phase 2 Readouts in Q3 2026 - AlphaStreet

Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart

Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha

ALLO Stock Jumps As Pivotal ALPHA3 CAR-T Data Loom - StocksToTrade

After layoffs, biotech exits 2 Boston-area leases - NBC Boston

Spyre Therapeutics Reports Positive Phase 2 Data for SPY001 in Ulcerative Colitis Trial - Quiver Quantitative

Allogene Therapeutics to Announce Interim Futility Analysis - GlobeNewswire

AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT - GlobeNewswire

INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - Yahoo Finance

Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative

OYE Therapeutics achieves first patient first dose in 505(b)(2) bridging study - Purdue Research Foundation

Oppenheimer Revises Soleno Therapeutics Price Target Amid Delayed US Launch - StocksToTrade

MiNK AACR study targets gastroesophageal cancer after PD-1 failure - Stock Titan

FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan

Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewswire

Rapport Therapeutics to Present New Phase 2 Treatment - GlobeNewswire

Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting - GlobeNewswire

United Therapeutics Soars as Clinical Trials Meet Key Endpoints - StocksToTrade

Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 | PSTV Stock News - Quiver Quantitative

ROIV

$30.41

1.27%

MRNA

$55.40

6.27%

BNTX

$89.50

1.43%

RPRX

$54.21

0.11%

ONC

$263.92

1.60%

RVMD

$156.58

2.17%

Yahooで開く | Google で開く | Finviz で開く | マーケットウォッチで開く | エドガーでオープン | ロイターで開く